Home

Translational research

Depression

Read time: 3 min

Congress highlights

Challenges and perspectives in the management of major depressive disorder: How can we bridge clinical predictors and biomarkers to better treatment outcomes for more patients?

Although the past 50 to 60 years of antidepressant drug development focusing on monoamines has...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Decline

Congress

Channels

Choose a channel

Go to Progress in Mind

Translational research

Challenges and perspectives in the management of major depressive disorder: How can we bridge clinical predictors and biomarkers to better treatment outcomes for more patients?

Channels

Choose a channel

Go to Progress in Mind

Select country

Translational research

Challenges and perspectives in the management of major depressive disorder: How can we bridge clinical predictors and biomarkers to better treatment outcomes for more patients?